Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

doi:10.1084/jem.181.2.619

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Baskar, S.
	Articles by Ostrand-Rosenberg, S.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Baskar, S.
	Articles by Ostrand-Rosenberg, S.


Social Bookmarking

	What's this?

ARTICLES

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

S Baskar, L Glimcher, N Nabavi, RT Jones and S Ostrand-Rosenberg
Department of Biological Sciences, University of Maryland, Baltimore 21228.

Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7- transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Bosch, J. J., Thompson, J. A., Srivastava, M. K., Iheagwara, U. K., Murray, T. G., Lotem, M., Ksander, B. R., Ostrand-Rosenberg, S. (2007). MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells. Cancer Res. 67: 4499-4506 [Abstract] [Full Text]
Dolan, B. P., Gibbs, K. D. Jr., Ostrand-Rosenberg, S. (2006). Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines. J. Immunol. 176: 1447-1455 [Abstract] [Full Text]
Thompson, J. A., Dissanayake, S. K., Ksander, B. R., Knutson, K. L., Disis, M. L., Ostrand-Rosenberg, S. (2006). Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain. Cancer Res. 66: 1147-1154 [Abstract] [Full Text]
Lim, W., Gee, K., Mishra, S., Kumar, A. (2005). Regulation of B7.1 Costimulatory Molecule Is Mediated by the IFN Regulatory Factor-7 through the Activation of JNK in Lipopolysaccharide-Stimulated Human Monocytic Cells. J. Immunol. 175: 5690-5700 [Abstract] [Full Text]
Dissanayake, S. K., Tuera, N., Ostrand-Rosenberg, S. (2005). Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome. J. Immunol. 174: 1811-1819 [Abstract] [Full Text]
Tanaka, Y., Koido, S., Ohana, M., Liu, C., Gong, J. (2005). Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells. J. Immunol. 174: 1274-1280 [Abstract] [Full Text]
von Bergwelt-Baildon, M., Schultze, J. L., Maecker, B., Menezes, I., Nadler, L. M., Lapointe, R., Thibodeau, J., Hwu, P. (2004). Correspondence re R. Lapointe et al., CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells. Cancer Res 2003;63:2836-43.. Cancer Res. 64: 4055-4057 [Full Text]
Dissanayake, S. K., Thompson, J. A., Bosch, J. J., Clements, V. K., Chen, P. W., Ksander, B. R., Ostrand-Rosenberg, S. (2004). Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy. Cancer Res. 64: 1867-1874 [Abstract] [Full Text]
Dolan, B. P., Phelan, T. P., Ilkovitch, D., Qi, L., Wade, W. F., Laufer, T. M., Ostrand-Rosenberg, S. (2004). Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines. J. Immunol. 172: 907-914 [Abstract] [Full Text]
Hu, H.-M., Winter, H., Ma, J., Croft, M., Urba, W. J., Fox, B. A. (2002). CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8+ T Cells. J. Immunol. 169: 4897-4904 [Abstract] [Full Text]
Lim, W., Ma, W., Gee, K., Aucoin, S., Nandan, D., Diaz-Mitoma, F., Kozlowski, M., Kumar, A. (2002). Distinct Role of p38 and c-Jun N-Terminal Kinases in IL-10-Dependent and IL-10-Independent Regulation of the Costimulatory Molecule B7.2 in Lipopolysaccharide-Stimulated Human Monocytic Cells. J. Immunol. 168: 1759-1769 [Abstract] [Full Text]
Osborne, A., Zhang, H., Yang, W.-M., Seto, E., Blanck, G. (2001). Histone Deacetylase Activity Represses Gamma Interferon-Inducible HLA-DR Gene Expression following the Establishment of a DNase I-Hypersensitive Chromatin Conformation. Mol. Cell. Biol. 21: 6495-6506 [Abstract] [Full Text]
Qi, L., Ostrand-Rosenberg, S. (2001). H2-O Inhibits Presentation of Bacterial Superantigens, but Not Endogenous Self Antigens. J. Immunol. 167: 1371-1378 [Abstract] [Full Text]
Ghia, P., Transidico, P., Veiga, J. P., Schaniel, C., Sallusto, F., Matsushima, K., Sallan, S. E., Rolink, A. G., Mantovani, A., Nadler, L. M., Cardoso, A. A. (2001). Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 98: 533-540 [Abstract] [Full Text]
Wallin, J. J., Liang, L., Bakardjiev, A., Sha, W. C. (2001). Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation. J. Immunol. 167: 132-139 [Abstract] [Full Text]
Christ, O., Matzku, S., Burger, C., Zöller, M. (2001). Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo. Clin. Cancer Res. 7: 1385-1397 [Abstract] [Full Text]
Todo, T., Martuza, R. L., Dallman, M. J., Rabkin, S. D. (2001). In Situ Expression of Soluble B7-1 in the Context of Oncolytic Herpes Simplex Virus Induces Potent Antitumor Immunity. Cancer Res. 61: 153-161 [Abstract] [Full Text]
Plautz, G. E., Mukai, S., Cohen, P. A., Shu, S. (2000). Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors. J. Immunol. 165: 3656-3662 [Abstract] [Full Text]
Stripecke, R., Cardoso, A. A., Pepper, K. A., Skelton, D. C., Yu, X.-J., Mascarenhas, L., Weinberg, K. I., Nadler, L. M., Kohn, D. B. (2000). Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96: 1317-1326 [Abstract] [Full Text]
Pulaski, B. A., Terman, D. S., Khan, S., Muller, E., Ostrand-Rosenberg, S. (2000). Cooperativity of Staphylococcal aureus Enterotoxin B Superantigen, Major Histocompatibility Complex Class II, and CD80 for Immunotherapy of Advanced Spontaneous Metastases in a Clinically Relevant Postoperative Mouse Breast Cancer Model. Cancer Res. 60: 2710-2715 [Abstract] [Full Text]
Braun, S. E., Chen, K., Foster, R. G., Kim, C. H., Hromas, R., Kaplan, M. H., Broxmeyer, H. E., Cornetta, K. (2000). The CC Chemokine CK{beta}-11/MIP-3{beta}/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells. J. Immunol. 164: 4025-4031 [Abstract] [Full Text]
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., Shields, J. (2000). Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity. J. Immunol. 164: 2160-2169 [Abstract] [Full Text]
Delgado, M., Sun, W., Leceta, J., Ganea, D. (1999). VIP and PACAP Differentially Regulate the Costimulatory Activity of Resting and Activated Macrophages Through the Modulation of B7.1 and B7.2 Expression. J. Immunol. 163: 4213-4223 [Abstract] [Full Text]
Santin, A. D., Hermonat, P. L., Ravaggi, A., Chiriva-Internati, M., Zhan, D., Pecorelli, S., Parham, G. P., Cannon, M. J. (1999). Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16-�and 18-Positive Cervical Cancer. J. Virol. 73: 5402-5410 [Abstract] [Full Text]
Zhang, H., Shepherd, A. T., Eason, D. D., Wei, S., Diaz, J. I., Djeu, J. Y., Wu, G. D., Blanck, G. (1999). Retinoblastoma Protein Expression Leads to Reduced Oct-1 DNA Binding Activity and Enhances Interleukin-8 Expression. Cell Growth Differ. 10: 457-465 [Abstract] [Full Text]
Mutis, T., Schrama, E., Melief, C. J.M., Goulmy, E. (1998). CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens. Blood 92: 1677-1684 [Abstract] [Full Text]
Chen, B.-g., Shi, Y., Smith, J. D., Choi, D., Geiger, J. D., Mule, J. J. (1998). The Role of Tumor Necrosis Factor alpha �in Modulating the Quantity of Peripheral Blood-Derived, Cytokine-Driven Human Dendritic Cells and Its Role in Enhancing the Quality of Dendritic Cell Function in Presenting Soluble Antigens to CD4+ T Cells In Vitro. Blood 91: 4652-4661 [Abstract] [Full Text]
Armstrong, T. D., Clements, V. K., Ostrand-Rosenberg, S. (1998). MHC Class II-Transfected Tumor Cells Directly Present Antigen to Tumor-Specific CD4+ T Lymphocytes1. J. Immunol. 160: 661-666 [Abstract] [Full Text]
Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P.-Y., Ostrand-Rosenberg, S. (1997). Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of�tumor-specific�immunity. Proc. Natl. Acad. Sci. USA 94: 6886-6891 [Abstract] [Full Text]